<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02702492</url>
  </required_header>
  <id_info>
    <org_study_id>KCP-9274-901</org_study_id>
    <nct_id>NCT02702492</nct_id>
  </id_info>
  <brief_title>PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)</brief_title>
  <acronym>PANAMA</acronym>
  <official_title>A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karyopharm Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and efficacy of oral KPT-9274 for the&#xD;
      treatment of patients with advanced solid malignancies or non-Hodgkin's lymphoma (NHL).&#xD;
      Currently enrolling melanoma patients in combination with nivolumab, only.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first-in-human, multi-center, open-label clinical study with separate Dose&#xD;
      Escalation and Expansion Phases to assess preliminary safety, tolerability, and efficacy of&#xD;
      KPT-9274, a dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies&#xD;
      (including sarcoma, colon, lung, melanoma, etc.) or NHL for which all standard therapeutic&#xD;
      options considered useful by the investigator have been exhausted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    sponsor decision&#xD;
  </why_stopped>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">June 1, 2021</completion_date>
  <primary_completion_date type="Actual">February 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) for KPT-9274 administered alone and with co-administration of niacin ER (extended release) (vitamin B3/nicotinic acid)</measure>
    <time_frame>Approximately 4 weeks</time_frame>
    <description>Parts A &amp; B: MTD will be based on the assessment of dose limiting toxicities (DLTs) during the first cycle of therapy and will be defined as the highest dose at which ≤1 participant out of 6 (or 0 out of 3) experiences DLTs within Cycle 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) for KPT-9274 co-administered with nivolumab</measure>
    <time_frame>Approximately 4 weeks</time_frame>
    <description>Part C: MTD will be based on the assessment of dose limiting toxicities (DLTs) during the first cycle of therapy and will be defined as the highest dose at which ≤ 1 participant out of 6 (or 0 out of 3) experiences DLTs within Cycle 1.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Solid Tumors</condition>
  <condition>NHL</condition>
  <arm_group>
    <arm_group_label>KPT-9274</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: [CLOSED TO ENROLLMENT]&#xD;
Oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KPT-9274 &amp; Niacin Extended Release (ER)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B:[CLOSED TO ENROLLMENT]&#xD;
500 mg niacin ER co-administered with each dose of oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KPT-9274 + Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part C:&#xD;
Oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle.&#xD;
Nivolumab 480 mg IV administered Day 1 during each 28 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KPT-9274</intervention_name>
    <arm_group_label>KPT-9274</arm_group_label>
    <arm_group_label>KPT-9274 &amp; Niacin Extended Release (ER)</arm_group_label>
    <arm_group_label>KPT-9274 + Nivolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niacin ER</intervention_name>
    <arm_group_label>KPT-9274 &amp; Niacin Extended Release (ER)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <arm_group_label>KPT-9274 + Nivolumab</arm_group_label>
    <other_name>Opdivo®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants must meet all of the following inclusion criteria to be eligible to enroll in&#xD;
        the Part C of this study.&#xD;
&#xD;
          1. Should have unresectable advanced, recurrent or metastatic melanoma and must have&#xD;
             objective and measurable melanoma by RECIST 1.1 after disease progression on a prior&#xD;
             anti-PD-1 or anti-PD-L1 therapy.&#xD;
&#xD;
          2. ECOG performance status of ≤ 2.&#xD;
&#xD;
          3. Life expectancy of ≥ 3 months.&#xD;
&#xD;
          4. Adequate hepatic function:&#xD;
&#xD;
               -  Total bilirubin &lt; 1.5 times the ULN (except participants with Gilbert's syndrome&#xD;
                  [hereditary indirect hyperbilirubinemia] who must have a total bilirubin of ≤ 3&#xD;
                  times ULN),&#xD;
&#xD;
               -  AST and ALT ≤ 2.5 times ULN (except participants with known liver involvement of&#xD;
                  their advanced solid malignancy who must have an AST and ALT ≤ 5.0 times ULN).&#xD;
&#xD;
          5. Adequate renal function:&#xD;
&#xD;
               -  Estimated creatinine clearance of ≥ 60 mL/min, calculated using the formula of&#xD;
                  Cockroft and Gault (140-Age) Mass (kg)/(72 creatinine mg/dL); multiply by 0.85 if&#xD;
                  female.&#xD;
&#xD;
          6. Adequate hematopoietic function:&#xD;
&#xD;
               -  Total WBC count ≥ 1500/mm³, ANC ≥ 1000/mm³, Hb ≥ 10.0 g/dL, platelet count ≥&#xD;
                  100,000/mm³&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants meeting any of the following exclusion criteria are not eligible to enroll in&#xD;
        this study.&#xD;
&#xD;
          1. ≤ 2 weeks since the last prior therapeutic regimen for melanoma. Palliative steroids&#xD;
             for disease related symptoms &lt; 7 days prior to C1D1, unless physiologic doses of&#xD;
             steroids are used.&#xD;
&#xD;
          2. Have not recovered or stabilized (Gr 1 or to their baseline for non-hematologic&#xD;
             toxicities, ≤ Gr 2 or to their baseline for hematologic toxicities) from toxicities&#xD;
             related to their previous treatment except for alopecia.&#xD;
&#xD;
          3. Untreated CNS disease or leptomeningeal involvement are excluded. Participants without&#xD;
             active brain or leptomeningeal metastases after prior treatment with local therapies&#xD;
             are eligible provided that the treatment had been done ≥ 2 weeks prior to enrollment.&#xD;
&#xD;
          4. Active infection with completion of therapeutic antibiotics, antivirals, or&#xD;
             antifungals within one week prior to C1D1. Prophylactic antibiotics, antivirals or&#xD;
             antifungals are permitted.&#xD;
&#xD;
          5. Significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting&#xD;
             or diarrhea that could interfere with the absorption of KPT-9274.&#xD;
&#xD;
          6. Active peptic ulcer disease or other active gastrointestinal bleeds.&#xD;
&#xD;
          7. Requiring treatment with corticosteroids at doses higher than substitute therapy (&gt; 10&#xD;
             mg prednisone), are unstable with substitute hormonal therapy, or are deemed to be&#xD;
             likely to re-occur by the treating physician when administered nivolumab.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jatin Shah, MD</last_name>
    <role>Study Director</role>
    <affiliation>Karyopharm Therapeutics Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Health</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University, Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU-Laura &amp; Isaac Perlmutter Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>100016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 3, 2016</study_first_submitted>
  <study_first_submitted_qc>March 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2016</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAK4</keyword>
  <keyword>KPT-9274</keyword>
  <keyword>Karyopharm</keyword>
  <keyword>NHL</keyword>
  <keyword>Solid Tumors</keyword>
  <keyword>NAMPT</keyword>
  <keyword>Melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

